Osteosarcoma remains the most common primary malignant bone tumor affecting children, adolescents, and young adults, characterized by aggressive progression and a heavy reliance on surgery combined with systemic therapy. As understanding of tumor biology deepens and new molecularly targeted candidates enter clinical development, the osteosarcoma market is entering a period of measurable transfor..